Vivos (RDGL) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document And Entity Information
Entity Registrant Name	VIVOS INC
Entity Central Index Key	0001449349
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		184,345,821
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 158,538	$ 5,494
Prepaid expenses	38,520	10,992
Total Current Assets	197,058	16,486
TOTAL ASSETS	197,058	16,486
Current Liabilities:
Accounts payable and accrued expenses	602,185	795,129
Related party accounts payable	38,710	38,610
Accrued interest payable	75,985	59,646
Payroll liabilities payable	80,000	11,451
Convertible notes payable, related party, net	11,475
Convertible notes payable, net	294,827	53,824
Promissory notes payable, net of discount	100,000
Related party promissory note	187,000
Total Current Liabilities	1,390,182	958,660
Total Liabilities	1,390,182	958,660
Commitments and contingencies
STOCKHOLDERS' DEFICIT
Common stock, par value, $0.001, 950,000,000 and 2,000,000,000 shares authorized, 178,585,821 and 163,445,736 issued and outstanding, respectively	178,586	163,446
Additional paid in capital - common stock	61,338,595	60,132,139
Accumulated deficit	(73,097,071)	(71,991,012)
Total Stockholders' Deficit	(1,193,124)	(942,174)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	197,058	16,486
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	2,553	2,553
Additional paid in capital - preferred stock	8,870,626	8,870,626
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	1,544	3,306
Additional paid in capital - preferred stock	836,765	1,876,768
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	821
Additional paid in capital - preferred stock	$ 674,457

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	2,000,000,000
Common stock, shares issued	178,585,821	163,445,736
Common stock, shares outstanding	178,585,821	163,445,736
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,552,642	2,552,642
Preferred stock, shares outstanding	2,552,642	2,552,642
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,543,245	3,305,755
Preferred stock, shares outstanding	1,543,245	3,305,755
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	821,292	0
Preferred stock, shares outstanding	821,292	0

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues, net	$ 8,000		$ 8,000
OPERATING EXPENSES
Sales and marketing expenses		750		13,700
Professional fees	87,075	16,223	356,248	231,501
Reserved stock units granted		19,515		104,410
Stock based compensation	457,949		463,917	45,400
Payroll expenses	30,000	82,500	90,000	243,570
Research and development	18,492	2,455	62,194	77,035
General and administrative expenses	21,691	15,463	41,067	49,884
Total Operating Expenses	615,207	136,906	1,013,426	765,500
OPERATING LOSS	(607,207)	(136,906)	(1,005,426)	(765,500)
NON-OPERATING INCOME (EXPENSE)
Interest expense	(96,271)	(60,752)	(134,739)	(5,626,892)
Net gain on debt extinguishment		394,618		526,222
Net loss on derivative liability		(27,109,374)		(27,976,982)
Forgiveness of debt	34,106		34,106
Grant income				17,583
Total Non-Operating Income (Expenses)	(62,165)	(26,775,508)	(100,633)	(33,060,069)
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(669,372)	(26,912,414)	(1,106,059)	(33,825,569)
Provision for income taxes
NET LOSS	$ (669,372)	$ (26,912,414)	$ (1,106,059)	$ (33,825,569)
Net loss per share - basic and diluted	$ 0	$ (0.56)	$ (0.01)	$ (1.49)
Weighted average common shares outstanding - basic	177,835,282	48,295,132	172,437,108	22,748,136

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders' Deficit - USD ($)	Series A Preferred [Member]	Additional Paid-In Capital - Series A Preferred [Member]	Series B Preferred [Member]	Additional Paid-In Capital - Series B Preferred [Member]	Series C Preferred [Member]	Additional Paid-In Capital - Series C Preferred [Member]	Common Stock [Member]	Additional Paid-In Capital - Common [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,779	$ 13,547,780					$ 8,212	$ 46,465,926	$ (64,288,167)	$ (4,262,470)
Balance, shares at Dec. 31, 2017	3,778,622						8,211,902
Stock issued for: Services							$ 1	448		449
Stock issued for: Services, shares							1,250
Conversion of preferred stock into common stock	$ (575)	(3,236,164)					$ 718	$ 3,236,021
Conversion of preferred stock into common stock, shares	(574,200)						717,750	(78)
Restricted units vested							$ 78
Restricted units vested, shares							77,500
Reserved shares for services								$ 52,094		$ 52,094
Options and warrants issued for services								23,766		23,766
Net income loss for the period									(901,185)	(901,185)
Balance at Mar. 31, 2018	$ 3,204	10,311,616					$ 9,009	49,778,177	(65,189,352)	(5,087,346)
Balance, shares at Mar. 31, 2018	3,204,422						9,008,402
Balance at Dec. 31, 2017	$ 3,779	13,547,780					$ 8,212	46,465,926	(64,288,167)	(4,262,470)
Balance, shares at Dec. 31, 2017	3,778,622						8,211,902
Net income loss for the period										(33,825,569)
Balance at Sep. 30, 2018	$ 2,770	9,498,134					$ 89,407	53,826,316	(98,113,736)	(34,697,109)
Balance, shares at Sep. 30, 2018	2,770,939						89,406,907
Balance at Dec. 31, 2017	$ 3,779	13,547,780					$ 8,212	46,465,926	(64,288,167)	(4,262,470)
Balance, shares at Dec. 31, 2017	3,778,622						8,211,902
Stock issued for: Services										$ 1,250
Stock issued for: Services, shares										449
Balance at Dec. 31, 2018	$ 2,553	8,870,626	$ 3,306	1,876,768			$ 163,446	60,132,139	(71,991,012)	$ (942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Balance at Mar. 31, 2018	$ 3,204	10,311,616					$ 9,009	49,778,177	(65,189,352)	(5,087,346)
Balance, shares at Mar. 31, 2018	3,204,422						9,008,402
Conversion of preferred stock into common stock	$ (393)	(735,811)					$ 490	735,714
Conversion of preferred stock into common stock, shares	(392,467)						490,584
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								32,801		32,801
Options and warrants issued for services								21,645		21,645
Stock issued for: Settlement of debt							$ 5,143	371,038		376,181
Stock issued for: Settlement of debt, shares							5,143,258
Net income loss for the period									(6,011,970)	(6,011,970)
Balance at Jun. 30, 2018	$ 2,811	9,575,805					$ 14,720	50,939,297	(71,201,322)	(10,668,689)
Balance, shares at Jun. 30, 2018	2,811,955						14,719,744
Conversion of preferred stock into common stock	$ (41)	(77,671)					$ 51	77,661
Conversion of preferred stock into common stock, shares	(41,016)						51,270
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								19,514		19,514
Stock issued for: Settlement of debt							$ 74,558	2,789,922		2,864,480
Stock issued for: Settlement of debt, shares							74,558,393
Net income loss for the period									(26,912,414)	(26,912,414)
Balance at Sep. 30, 2018	$ 2,770	9,498,134					$ 89,407	53,826,316	(98,113,736)	(34,697,109)
Balance, shares at Sep. 30, 2018	2,770,939						89,406,907
Conversion of preferred stock into common stock	$ (217)	(627,508)					$ 273	627,452
Conversion of preferred stock into common stock, shares	(218,297)						272,872
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								8,779		8,779
Options and warrants issued for services								1,279,675		1,279,675
Stock issued for: Settlement of debt			$ 2,996	1,542,078			$ 48,827	2,346,420		3,940,321
Stock issued for: Settlement of debt, shares			2,995,755				48,827,137
Stock issued for: Cash			$ 110	54,890			$ 17,078	666,062		738,140
Stock issued for: Cash, shares			110,000				17,078,500
Stock issued for: Accounts payable and accrued expenses			$ 200	279,800			$ 7,783	1,377,513		1,665,296
Stock issued for: Accounts payable and accrued expenses, shares			200,000				7,782,820
Net income loss for the period									26,122,724	26,122,724
Balance at Dec. 31, 2018	$ 2,553	8,870,626	$ 3,306	1,876,768			$ 163,446	60,132,139	(71,991,012)	(942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Conversion of preferred stock into common stock			$ (524)	(209,163)			$ 6,553	203,134
Conversion of preferred stock into common stock, shares			(524,218)				6,552,725
Options and warrants issued for services								3,792		3,792
Stock issued for: Cash			$ 100	49,900			$ 1,250	48,750		100,000
Stock issued for: Cash, shares			100,000				1,250,000
Conversion of Series B Preferred into Series C Preferred			$ (821)	(674,457)	$ 821	674,457
Conversion of Series B Preferred into Series C Preferred, shares			(821,292)		821,292
Warrants issued with notes payable (discount)								28,721		28,721
Net income loss for the period									(236,382)	(236,382)
Balance at Mar. 31, 2019	$ 2,553	8,870,626	$ 2,061	1,043,048	$ 821	674,457	$ 171,249	60,416,536	(72,227,394)	(1,046,043)
Balance, shares at Mar. 31, 2019	2,552,642		2,060,245		821,292		171,248,461
Balance at Dec. 31, 2018	$ 2,553	8,870,626	$ 3,306	1,876,768			$ 163,446	60,132,139	(71,991,012)	(942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Net income loss for the period										(1,106,059)
Balance at Sep. 30, 2019	$ 2,553	8,870,626	$ 1,544	836,765	$ 821	674,457	$ 178,586	61,338,595	(73,097,071)	(1,193,124)
Balance, shares at Sep. 30, 2019	2,552,642		1,543,245		821,292		178,585,821
Balance at Mar. 31, 2019	$ 2,553	8,870,626	$ 2,061	1,043,048	$ 821	674,457	$ 171,249	60,416,536	(72,227,394)	(1,046,043)
Balance, shares at Mar. 31, 2019	2,552,642		2,060,245		821,292		171,248,461
Conversion of preferred stock into common stock			$ (517)	(206,283)			$ 6,462	200,338
Conversion of preferred stock into common stock, shares			(517,000)				6,462,500
Options and warrants issued for services								2,176		2,176
Warrants issued with notes payable (discount)								12,592		12,592
Adjustment for fractional shares in reverse split
Adjustment for fractional shares in reverse split, Shares							(140)
Net income loss for the period									(200,305)	(200,305)
Balance at Jun. 30, 2019	$ 2,553	8,870,626	$ 1,544	836,765	$ 821	674,457	$ 177,711	60,631,642	(72,427,699)	(1,231,580)
Balance, shares at Jun. 30, 2019	2,552,642		1,543,245		821,292		177,710,821
Stock issued for: Services							$ 312	12,188		12,500
Stock issued for: Services, shares							312,500
Options and warrants issued for services								457,949		457,949
Options issued for settlement of accounts payable								33,829		33,829
Stock issued for: Accounts payable and accrued expenses							$ 563	21,937		22,500
Stock issued for: Accounts payable and accrued expenses, shares							562,500
Warrants issued with notes payable (discount)								95,437		95,437
Warrants issued for extension of notes payable								25,656		25,656
BCF recognized on convertible notes								59,957		59,957
Net income loss for the period									(669,372)	(669,372)
Balance at Sep. 30, 2019	$ 2,553	$ 8,870,626	$ 1,544	$ 836,765	$ 821	$ 674,457	$ 178,586	$ 61,338,595	$ (73,097,071)	$ (1,193,124)
Balance, shares at Sep. 30, 2019	2,552,642		1,543,245		821,292		178,585,821

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended					9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
CASH FLOW FROM OPERATING ACTIVIITES
Net loss	$ (669,372)	$ (236,382)	$ 26,122,724	$ (26,912,414)	$ (901,185)	$ (1,106,059)	$ (33,825,569)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of convertible debt discount						66,969	791,937
Amortization of BCF discount						16,327
Common stock issued for services						12,500	449
Stock options and warrants for services						489,573	45,400
Reserved stock units issued for services				19,515			104,410
Derivatives recorded as loan fees							4,636,517
(Gain) on debt extinguishment				(394,618)			(526,222)
Forgiveness of debt	(34,106)					(34,106)
Loss of derivative liability				27,109,374			27,976,982
Changes in assets and liabilities
Prepaid expenses and other assets						(27,528)	(4,351)
Accounts payable and accrued expenses						(101,620)	239,596
Accounts payable and accrued expenses from related party						15,100	(9,955)
Payroll liabilities						68,549	204,550
Accrued interest						16,339	198,448
Total adjustments						522,103	33,657,761
Net cash used in operating activities						(583,956)	(167,808)
CASH FLOWS FROM FINANCING ACTIVITES
Proceeds from promissory notes						450,000
Proceeds from related party notes payable						187,000
Proceeds from sale of preferred stock						50,000
Proceeds from sale of common stock						50,000
Proceeds from convertible debt							50,000
Proceeds from promissory notes - related party, net of repayments							109,491
Net cash provided by financing activities						737,000	159,491
NET INCREASE (DECREASE) IN CASH						153,044	(8,317)
CASH - BEGINNING OF PERIOD		$ 5,494			$ 8,317	5,494	8,317	$ 8,317
CASH - END OF PERIOD	$ 158,538		$ 5,494			158,538		$ 5,494
CASH PAID DURING THE PERIOD FOR:
Interest expense						4,000
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of preferred stock into common stock						416,487	4,050,654
Conversion of convertible preferred B into convertible preferred C						675,278
Recognition of debt discount at inception of notes payable						136,750
Recognition of BCF discount at inception of notes payable						59,957
Common stock issued in settlement of accounts payable						22,500
Stock options issued in settlement of accounts payable						33,829
Vesting of restricted stock units							1,860
Reclassification of shareholder advances to convertible notes payable						15,000	32,279
Conversion of notes payable and accrued interest into common stock							$ 3,240,661

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES The accompanying condensed financial statements of Vivos Inc. (the “ Company Effective June 28, 2019, FINRA approved the Company’s reverse 1 for 8 stock-split. The reverse stock split will enable the Company to issue additional shares now that there is availability to do so. All share and per-share figures herein have been restated to take effect for this reverse stock-split. In April of 2017, the Company filed a Certificate of Merger with the Delaware Division of Corporations in order to merge the Company’s wholly-owned subsidiary, IsoPet Solutions Corporation, with and into the Company. The Company therefore no longer prepares Consolidated Financial Statements. The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device RadioGel™ for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. The Company’s current focus is on the development of its RadioGel™ device. RadioGel™ is an injectable particle-gel, for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“ Y-90 The Company’s lead brachytherapy products, including RadioGel™, incorporate patented technology developed for Battelle Memorial Institute (“ Battelle Battelle License The Company is currently focusing on obtaining approval from the Food and Drug Administration ( “FDA” In February 2014, the FDA ruled the device as not substantially equivalent due to a lack of a predicate device and it was therefore classified as a Class III device. Class III devices are generally the highest risk devices and are therefore subject to the highest level of regulatory review, control and oversight. Class III devices must typically be approved by the FDA before they are marketed. Class II devices represent lower risk devices than Class III and require fewer regulatory controls to provide reasonable assurance of the device’s safety and effectiveness. In contrast, Class I devices are deemed to be lower risk than Class II or III and are therefore subject to the least regulatory controls. The Company is currently developing test plans to address issues raised by the FDA in connection with the Company’s previous submissions regarding RadioGel™, including developing specific test plans and specific indication of use. The Company intends to request that the FDA grant approval to re-apply for de novo See also Annual Report IsoPet Solutions The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017. To date, five dogs, representing six therapies (one repeat therapy), have been treated with IsoPet® at the University of Missouri. In addition, five cats have been treated at Washington State University and one cat at Vista which resulted in revenue of $8,000 (see below) at Vista. The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP. On July 10, 2019, the Company recognized its first commercial sale of IsoPet®. A doctor brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale of $8,000 met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications. Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Inventory Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consisted of finished goods. The Company has no inventory for the nine-months ended September 30, 2019 and for the year ended December 31, 2018. Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2019 and December 31, 2018, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis. Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date. Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down. License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%). Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per 2019 $ 10,000 2020 10,000 2021 10,000 2022 4,000 Total $ 34,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The Company entered into a Letter Amendment #2 with Battelle Memorial Institute on December 20, 2018. as a result of this Amendment, the Company has agreed to revised terms regarding the license fee as indicated in the chart above. $10,000 of this fee due within 1 year relates to the 2018 license fee which was paid in January 2019. The Company also agreed to change the royalty fee on net sales back to 1% on October 8, 2019. Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the nine-months ended September 30, 2019 and 2018, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. Income from Grants and Deferred Income Government grants are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Company has chosen to recognize income from grants as it incurs costs associated with those grants, and until such time as it recognizes the grant as income those funds received will be classified as deferred income on the balance sheet. On December 22, 2017, the Company received notification that Washington State University awarded it $17,500 of grant funds from the sub-award project entitled “ Optimized Injectable Radiogels for High-dose Therapy of Non-Resectable Solid Tumors Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine and three months ended September 30, 2019 and 2018, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of September 30, 2019 and December 31, 2018, which include the following: September 30, 2019 December 31, 2018 Convertible debt 9,465,196 17,594 Preferred stock 32,747,515 44,512,740 Common stock options 34,154,271 11,318,021 Common stock warrants 30,161,847 23,052,472 Total potential dilutive securities 106,528,829 78,900,827 Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $62,194 and $77,035 research and development costs for the nine-months ended September 30, 2019, and 2018, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the three and nine months then ended. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed for the nine-months ended September 30, 2019 and 2018, respectively. During the nine-months ended September 30, 2019 and 2018, the Company incurred $0 and $13,700, respectively, in advertising and marketing costs. Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of materials. Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. See Note 9 – Legal Matters for description of lawsuit filed against the Company on January 28, 2019. In addition, the Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2019 and 2018. Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the nine-months ended September 30, 2019 and 2018. The Company did not have any deferred tax liability or asset on its balance sheet on September 30, 2019 and December 31, 2018. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the nine-months ended September 30, 2019 and 2018, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Tax Cuts and Jobs Act (the “ Act These amounts are provisional and subject to change. The most significant impact of the legislation for the Company was a $3,300,000 reduction of the value of net deferred tax assets (which represent future tax benefits) as a result of lowering the U.S. corporate income tax rate from 35% to 21%. The Act also includes a requirement to pay a one-time transition tax on the cumulative value of earnings and profits that were previously not repatriated for U.S. income tax purposes. The Company has no earnings and profits that were previously not repatriated for U.S. income tax purposes. Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation – Stock Compensation. Under FASB ASC Topic. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-04, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-04 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements,” which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2: GOING CONCERN The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.3 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to: (1) fund the FDA approval process and initial deployment of the brachytherapy products, and (2) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises. Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company has completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019 which will enable them to begin the process of raising capital through their Regulation A+ which was filed with the Securities and Exchange Commission (“SEC”) now that the Company has available authorized shares to issue and is currently pending approval. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Fixed Assets	NOTE 3: FIXED ASSETS Fixed assets consist of the following at September 30, 2019 (unaudited) and December 31, 2018: September 30, 2019 December 31, 2018 Production equipment $ - $ 15,182 Less accumulated depreciation (- ) (15,182 ) $ - $ - There is no depreciation expense for the above fixed assets for the nine months ended September 30, 2019 and 2018, respectively. In June 2019, the Company sold the one piece of equipment still held for $0. The basis of this piece of equipment was also $0, resulting in no gain or loss on the sale.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 4: RELATED PARTY TRANSACTIONS Related Party Convertible Notes Payable As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following related party convertible notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued September 2019 $15,000 Note, 8% interest, due January 2020 $ 15,000 $ 36 $ - $ - Other related party notes - 1,054 - 1,054 March 2017 $332,195 Note, 10% interest, due May 2017 - - - - Total Convertible Notes Payable, Net $ 15,000 $ 1,090 $ - $ 1,054 Less: Debt Discount (3,525 ) - - - $ 11,475 $ 1,090 $ - $ 1,054 In March 2017, the Company combined Outstanding Notes owed to a director and major stockholder, along with $51,576 of accrued interest payable, into one promissory note (the “ Related Party Note Qualified Financing The Company has outstanding accrued interest in the amount of $1,054 from old related party notes that the principal had been paid off in full. The Company from time to time receives non-interest bearing advancers from its Chief Executive Officer that are due on demand. During the nine months ended September 30, 2019, the Company received $20,000 in advances and repaid $5,000 of these and had $15,000 outstanding at September 24, 2019. On September 24, 2019, these advances were converted into a convertible note at 8% interest which matures January 15, 2020. Interest on this note for the period ended September 30, 2019 amounted to $36, and this amount is accrued at September 30, 2019. The Chief Executive Officer received 150,000 warrants when the advances were converted into this convertible note payable. The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020. Interest expense for the nine-months ended September 30, 2019 and 2018 on the related party convertible notes payable amounted to $36 and $28,704, respectively. Related Party Notes Payable As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following related party notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued January 2019 $60,000 Note, 8% interest, due January 2020 $ 60,000 $ 3,266 $ - $ - March 2019 $48,000 Note, 8% interest, due March 2020 48,000 1,962 - - April 2019 $29,000 Note, 8% interest, due April 2020 29,000 976 - - July 2019 $50,000 Note 8% interest, due July 2020 50,000 951 - - Total Related Party Notes Payable, Net $ 187,000 $ 7,155 $ - $ - On January 24, 2019 the Company entered into a note payable with a trust related to one of the Company’s directors in the amount of $60,000. The note is for a one-year period maturing January 24, 2020 and bears interest at an annual rate of 8.00%. On March 27, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $48,000. The note is for a one-year period maturing March 27, 2020 and bears interest at an annual rate of 8%. On April 29, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $29,000. On July 5, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $50,000. The note is for a one-year period maturing July 5, 2020 and bears interest at an annual rate of 8%. Interest expense for these notes for the nine-months ended September 30, 2019 and accrued interest at September 30, 2019 is $7,155. Related Party Payables The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $38,710 and $38,610 as of September 30, 2019 (unaudited) and December 31, 2018, respectively. Preferred and Common Shares Issued to Officers and Directors During 2018, the Company issued 4,832,820 shares of common stock and warrants to purchase shares of common stock totaling 2,416,410 in settlement of accrued compensation valued at $541,276. The warrants were valued at $238,973 and the Company reflected $586,936 as a loss on conversion of debt. During 2018, the Company issued 450,000 shares of common stock in settlement of accounts payable and notes payable valued at $50,400. The Company granted 225,000 warrants in connection with this transaction and recognized a loss of $35,400 in accordance with this settlement.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5: CONVERTIBLE NOTES PAYABLE As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following convertible notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 38,631 $ 45,000 34,603 May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015 - 17,341 - 17,341 October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively - 5,953 - 5,953 January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016 - 696 - 696 May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019 60,000 1,600 - - July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 874 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 230 - - September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 38,000 174 - - September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 25,000 109 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 208 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 197 - - September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 37,000 89 - - Penalties on notes in default 10,166 - 8,824 - Total Convertible Notes Payable, Net $ 415,166 $ 66,102 $ 53,824 $ 58,593 Less: Original Issue Discount (1,970 ) - - - Less: BCF Discount (43,630 ) - - - Less: Debt Discount (74,739 ) - - - $ 294,827 $ 66,102 $ 53,824 $ 58,593 Interest expense for the nine-months ended September 30, 2019 and 2018 on the convertible notes payable amounted to $7,509 and $100,826, respectively. The May 2017 notes totaling $3,136,506, $2,419,240 after debt discounts, had a December 2017 due date which was extended to May 2018. The November 2017 Note totaling $166,666, $92,004 after debt discount, included an Investor’s Put Option whereby if the Company’s stock was not listed on the Nasdaq or NYSE by January 31, 2018, the lender had the right to require the Company to repurchase the Note at any time after January 31, 2018 in an amount equal to 130% of the sum of the Principal plus all accrued and unpaid interest. The Investor issued notice February 2, 2018 exercising it’s Put Option and requiring the Company repurchase the Note on April 19, 2018 in the aggregate amount of $228,332. The investor may elect to cancel the repurchase notice at any time prior to receiving the repurchase payment. On October 10, 2018, the Company successfully completed the terms of the Path Forward Agreements The Company entered into a convertible note in the amount of $50,000 in July 2018 with an interest rate of 8%. This note was convertible upon a Company capital raise of at least $500,000. On October 30, 2018, the Company converted this note into 1,500,000 shares of common stock at a conversion rate of $0.112 (total of $60,000 which includes $10,000 of interest and other costs) and recognized a loss on extinguishment of $108,916 on this conversion. The Company entered into a $50,000 convertible promissory note dated May 31, 2019, that matures October 30, 2019. The convertible promissory note bears interest at a rate of 8%, The convertible promissory note is convertible into shares of common stock at a price of $0.032 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory note together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The $10,000 contingent exchange amount is classified as original issue discount and will be amortized over the life of the convertible promissory note. The convertible promissory noteholder received 625,000 warrants at an exercise price of $0.04 per share, that have a term of two years. The warrants were valued at $12,592 and represent a debt discount, which will be amortized over the life of the convertible promissory note. The Company entered into $300,000 in convertible promissory note in July and September 2019, that mature January 15, 2020. The convertible promissory notes bear interest at a rate of 8%, The convertible promissory notes are convertible into shares of common stock at a price of $0.04 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory notes together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The convertible promissory noteholders received 3,000,000 warrants at an exercise price ranging between $0.06 and $0.08 per share, that have a term of two years. The warrants were valued at $91,716 and represent a debt discount, which will be amortized over the life of the convertible promissory notes. In addition, the Company recognized a beneficial conversion feature discount to the notes of $59,957 that is being amortized over the life of the notes. For the period ended September 30, 2019, the Company recognized $16,327 in amortization of the BCF discount.

Promissory Notes Payable

Promissory Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Promissory Notes Payable	NOTE 6: PROMISSORY NOTES PAYABLE As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following promissory notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued February 2019, two promissory notes for $50,000 each (total of $100,000), maturing August 2019, extended to February 2020, at 8.00% interest (originally) and now 15% interest $ 100,000 $ 1,640 $ - - Debt discount (- ) - - - Total Promissory Notes Payable, Net $ 100,000 $ 1,640 $ - $ - The Company issued two separate promissory notes on February 20, 2019 at $50,000 each (total of $100,000) that mature on August 20, 2019 and accrue interest at 8.00% per annum. Interest expense for the six-months ended June 30, 2019 on the promissory notes and accrued at June 30, 2019 amounted to $2,842. In connection with the promissory notes, the Company issued warrants to purchase 1,250,000 shares of common stock. The Company recorded the relative fair value of the warrants as a debt discount of $28,721 and amortized the discount over the life of the note (6 months). Amortization of debt discount for the nine-months ended September 30, 2019 was $28,721 and is recorded as interest expense on the statement of operations for the nine-months ended September 30, 2019. On August 20, 2019, the two noteholders agreed to extend these notes another six-months and the notes now mature February 20, 2020. In consideration for the extension, the note holders will receive 750,000 warrants (375,000 each) and the interest rate on the notes increased from 8% to 15% per annum. The accrued interest at August 20, 2019 of $4,000 was paid to the note holders.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Deficit	NOTE 7: STOCKHOLDERS’ DEFICIT Common Stock The Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of September 30, 2019 and December 31, 2018, the Company has 178,585,821 and 163,445,736 shares issued and outstanding, respectively. On March 28, 2019, the Company’s board of directors approved a reverse 1-for-8 stock split, and a decrease in the authorized shares from 2,000,000,000 to 950,000,000. The reverse stock split went effective by FINRA on June 28, 2019. Preferred Stock As of September 30, 2019 and December 31, 2018, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. Series A Convertible Preferred Stock (“Series A Convertible Preferred”) In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from 2,500,000 shares to 5,000,000 shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred: Liquidation Preference Dividends Conversion Series A Conversion Shares In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares. Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series B Convertible Preferred Stock (“Series B Convertible Preferred”) In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred: Liquidation Preference Dividends Conversion Series B Conversion Shares Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series C Convertible Preferred Stock (“Series C Convertible Preferred”) In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred: Liquidation Preference Dividends Conversion Series C Conversion Shares The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“ Authorized Share Approval Initial Convertibility Date Conversion Rights Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Common and Preferred Stock Issuances - 2019 In January 2019, the Company received $100,000 in gross proceeds resulting from the issuance to accredited investors of 1,250,000 shares of common stock, 100,000 shares of Series B Convertible Preferred and warrants to purchase 1,250,000 shares of common stock. The Company issued 13,015,225 shares of common stock in consideration for the conversion of 1,041,218 shares of Series B Convertible Preferred. The Company issued 821,292 shares of Series C Convertible Preferred in exchange for 821,292 shares of Series B Convertible Preferred. The Company issued 562,500 shares of common stock in a settlement of accounts payable valued at $22,500. The Company issued 312,500 shares of common stock for services rendered in connection with the raising of debt instruments valued at $12,500. Common and Preferred Stock Issuances - 2018 During 2018, the Company issued 1,250 shares of common stock for services valued at $449. During 2018, the Company issued 128,528,788 shares of common stock and 2,995,755 shares of Series B Convertible Preferred in conjunction with the settlement of $3,545,378 worth of convertible debt (both related and non-related) and $506,245 worth of accrued interest (both related and non-related). As part of these conversions, the Company recognized offsets of $4,823,363 for derivative liabilities and recognized a gain on extinguishment of debt of $1,694,005. During 2018, the Company issued 1,532,476 shares of common stock valued at $4,678,380 in exchange for 1,225,981 shares of Series A Convertible Preferred. During 2018, the Company issued 17,078,500 shares of common stock for cash in the amount of $683,140. During 2018, the Company issued 110,000 shares of Series B Convertible Preferred for cash in the amount of $55,000. During 2018, 7,782,820 shares of common stock and 200,000 shares of Series B Convertible Preferred were issued to officers and consultants for accrued compensation as well as to settle accounts payable and shareholder advances made during the year. The value of these shares were $1,665,285. The Company recognized a loss on extinguishment on these issuances of $1,256,972.

Common Stock Options, Warrants

Common Stock Options, Warrants and Restricted Stock Units	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Common Stock Options, Warrants and Restricted Stock Units	NOTE 8: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Common Stock Options The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests. The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2018 11,318,021 $ 0.112-120.00 6.75 years $ - $ 0.24 Options granted 22,882,500 $ 0.029 - $ - Options exercised - $ - - $ - Options expired (46,250 ) $ - - $ - Balance at September 30, 2019 34,154,271 $ 0.024-120.00 6.40 years $ 297,217 $ 0.15 Exercisable at September 30, 2019 28,713,021 $ 0.024-120.00 6.46 years $ 221,583 $ 0.15 In June 2019, the Company issued 382,500 stock options to consultants that vest through June 30, 2020. The grant date of these options was June 17, 2019, the date of board approval. On June 21, 2019, 46,250 stock options expired that were issued June 21, 2016. The Company has granted 21,000,000 stock options under the Company’s 2015 Omnibus Securities and Incentive Plan to Dr. Korenko. The granting of the stock options occurs 10 days after the approval of the Company’s recent 1 for 8 reverse stock split that occurred on June 28, 2018. The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019, and December 31, 2019); (ii) 25% upon the Company filing a patent (completed on July 1, 2019); and (iii) 25% upon the first commercial sale of IsoPet ® In September 2019, the Company granted 1,000,000 stock options in a settlement agreement for past due legal fees. The options have a ten-year life and vest immediately. These options were valued at $33,829 which offset accounts payable. In September 2019, the Company granted 500,000 stock options to a consultant for services rendered. The options have a ten-year life and vest immediately. These options were valued at $16,915. During the nine months ended September 30, 2019 and 2018, the Company recognized $460,125 and $45,400 worth of stock based compensation related to the vesting of its stock options. Common Stock Warrants The following schedule summarizes the changes in the Company’s stock warrants: Warrants Outstanding Weighted Average Aggregate Weighted Number Of Shares Exercise Price Per Share Contractual Life Intrinsic Value Exercise Price Per Share Balance at December 31, 2018 23,052,472 $ 0.08-80.00 1.77 years $ - $ 0.08 Warrants granted 7.109,375 $ 0.04-0.08 - $ 0.06 Warrants exercised - $ - - $ Warrants expired/cancelled - $ - - $ Balance at September 30, 2019 30,161,847 $ 0.04-80.00 1.18 years $ - $ 0.10 Exercisable at September 30, 2019 30,161,847 $ 0.04-80.00 1.18 years $ - $ 0.10 For the nine months ended September 30, 2019, the Company granted 1,250,000 warrants in the issuance of common and preferred shares issued for cash to accredited investors, 5,025,000 warrants in the issuance of promissory notes (recorded as a debt discount valued at $136,749), 750,000 warrants for the extension of promissory notes, recorded as interest expense valued at $25,656 and 84,375 warrants issued for consulting services valued at $3,792. Restricted Stock Units The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2018 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at September 30, 2019 262,500 $ 0.59 During the nine months ended September 30. 2019 and 2018, the Company recognized $0 and $104,410 worth of expense related to the vesting of its RSU’s. As of September 30, 2019, the Company had $155,400 worth of expense yet to be recognized for RSU’s not yet vested.

Legal Matters

Legal Matters	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 9: LEGAL MATTERS On January 28, 2019, James Katzaroff, (“ Plaintiff Release Complaint

Commitment

Commitment	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitment	NOTE 10: COMMITMENT On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $180,000. Of this amount, $120,000 is booked in monthly intervals and the remaining balance is only paid upon the Company achieving a cash balance that exceeds $1,000,000. The Company has elected to record the compensation as $120,000, and upon achieving the milestone of $1,000,000 in cash balances, will record the deferred compensation at that time. In addition to the cash compensation, The Company has granted 21,000,000 stock options under the Company’s 2015 Omnibus Securities and Incentive Plan to Dr. Korenko. The granting of the stock options occurs 10 days after the approval of the Company’s recent 1 for 8 reverse stock split that occurred on June 28, 2018. The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019 and December 31, 2019); (ii) 25% upon the Company filing a patent; and (iii) 25% upon the first commercial sale of IsoPet ®

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 11: SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date of this filing pursuant to ASC Topic 855 and has determined that, except as disclosed herein, there are no additional subsequent events to disclose. On October 8, 2019, the Company and Battelle Memorial Institute entered into Amendment 3 of the License Agreement. In accordance with the amendment, the parties agreed to decrease the royalty from two percent (2%) to one percent (1%) on net sales and amended the minimum royalties through 2022. In October 2019, the Company issued 5,375,000 shares of Common Stock in conversion of 430,000 shares of Series B Convertible Preferred Stock. In October 2019, the Company issued 385,000 shares of Common Stock in the exercise of RSU’s.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Financial Statement Reclassification	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.
Cash Equivalents	Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
Inventory	Inventory Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consisted of finished goods. The Company has no inventory for the nine-months ended September 30, 2019 and for the year ended December 31, 2018.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2019 and December 31, 2018, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.
Derivative Liabilities and Beneficial Conversion Feature	Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date.
Fixed Assets	Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.
License Fees	License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%). Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per 2019 $ 10,000 2020 10,000 2021 10,000 2022 4,000 Total $ 34,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The Company entered into a Letter Amendment #2 with Battelle Memorial Institute on December 20, 2018. as a result of this Amendment, the Company has agreed to revised terms regarding the license fee as indicated in the chart above. $10,000 of this fee due within 1 year relates to the 2018 license fee which was paid in January 2019. The Company also agreed to change the royalty fee on net sales back to 1% on October 8, 2019.
Patents and Intellectual Property	Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the nine-months ended September 30, 2019 and 2018, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.
Income from Grants and Deferred Income	Income from Grants and Deferred Income Government grants are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Company has chosen to recognize income from grants as it incurs costs associated with those grants, and until such time as it recognizes the grant as income those funds received will be classified as deferred income on the balance sheet. On December 22, 2017, the Company received notification that Washington State University awarded it $17,500 of grant funds from the sub-award project entitled “ Optimized Injectable Radiogels for High-dose Therapy of Non-Resectable Solid Tumors
Loss Per Share	Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine and three months ended September 30, 2019 and 2018, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of September 30, 2019 and December 31, 2018, which include the following: September 30, 2019 December 31, 2018 Convertible debt 9,465,196 17,594 Preferred stock 32,747,515 44,512,740 Common stock options 34,154,271 11,318,021 Common stock warrants 30,161,847 23,052,472 Total potential dilutive securities 106,528,829 78,900,827
Research and Development Costs	Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $62,194 and $77,035 research and development costs for the nine-months ended September 30, 2019, and 2018, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the three and nine months then ended.
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed for the nine-months ended September 30, 2019 and 2018, respectively. During the nine-months ended September 30, 2019 and 2018, the Company incurred $0 and $13,700, respectively, in advertising and marketing costs.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of materials.
Contingencies	Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. See Note 9 – Legal Matters for description of lawsuit filed against the Company on January 28, 2019. In addition, the Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2019 and 2018.
Income Taxes	Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the nine-months ended September 30, 2019 and 2018. The Company did not have any deferred tax liability or asset on its balance sheet on September 30, 2019 and December 31, 2018. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the nine-months ended September 30, 2019 and 2018, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Tax Cuts and Jobs Act (the “ Act These amounts are provisional and subject to change. The most significant impact of the legislation for the Company was a $3,300,000 reduction of the value of net deferred tax assets (which represent future tax benefits) as a result of lowering the U.S. corporate income tax rate from 35% to 21%. The Act also includes a requirement to pay a one-time transition tax on the cumulative value of earnings and profits that were previously not repatriated for U.S. income tax purposes. The Company has no earnings and profits that were previously not repatriated for U.S. income tax purposes.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation – Stock Compensation. Under FASB ASC Topic. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-04, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-04 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements,” which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Depreciation Estimated Useful Life	Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years
Schedule of Future Minimum Royalties	Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per 2019 $ 10,000 2020 10,000 2021 10,000 2022 4,000 Total $ 34,000
Schedule of Dilutive Earnings Per Share	The following represent common stock equivalents that could be dilutive in the future as of September 30, 2019 and December 31, 2018, which include the following: September 30, 2019 December 31, 2018 Convertible debt 9,465,196 17,594 Preferred stock 32,747,515 44,512,740 Common stock options 34,154,271 11,318,021 Common stock warrants 30,161,847 23,052,472 Total potential dilutive securities 106,528,829 78,900,827

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2019 (unaudited) and December 31, 2018: September 30, 2019 December 31, 2018 Production equipment $ - $ 15,182 Less accumulated depreciation (- ) (15,182 ) $ - $ -

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Transaction	As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following related party convertible notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued September 2019 $15,000 Note, 8% interest, due January 2020 $ 15,000 $ 36 $ - $ - Other related party notes - 1,054 - 1,054 March 2017 $332,195 Note, 10% interest, due May 2017 - - - - Total Convertible Notes Payable, Net $ 15,000 $ 1,090 $ - $ 1,054 Less: Debt Discount (3,525 ) - - - $ 11,475 $ 1,090 $ - $ 1,054 As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following related party notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued January 2019 $60,000 Note, 8% interest, due January 2020 $ 60,000 $ 3,266 $ - $ - March 2019 $48,000 Note, 8% interest, due March 2020 48,000 1,962 - - April 2019 $29,000 Note, 8% interest, due April 2020 29,000 976 - - July 2019 $50,000 Note 8% interest, due July 2020 50,000 951 - - Total Related Party Notes Payable, Net $ 187,000 $ 7,155 $ - $ -

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following convertible notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 38,631 $ 45,000 34,603 May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015 - 17,341 - 17,341 October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively - 5,953 - 5,953 January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016 - 696 - 696 May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019 60,000 1,600 - - July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 874 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 230 - - September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 38,000 174 - - September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 25,000 109 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 208 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 197 - - September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 37,000 89 - - Penalties on notes in default 10,166 - 8,824 - Total Convertible Notes Payable, Net $ 415,166 $ 66,102 $ 53,824 $ 58,593 Less: Original Issue Discount (1,970 ) - - - Less: BCF Discount (43,630 ) - - - Less: Debt Discount (74,739 ) - - - $ 294,827 $ 66,102 $ 53,824 $ 58,593

Promissory Notes Payable (Table

Promissory Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Promissory Notes Payable, Net	As of September 30, 2019 (unaudited) and December 31, 2018, the Company had the following promissory notes outstanding: September 30, 2019 December 31, 2018 Principal Accrued Principal Accrued February 2019, two promissory notes for $50,000 each (total of $100,000), maturing August 2019, extended to February 2020, at 8.00% interest (originally) and now 15% interest $ 100,000 $ 1,640 $ - - Debt discount (- ) - - - Total Promissory Notes Payable, Net $ 100,000 $ 1,640 $ - $ -

Common Stock Options, Warrant_2

Common Stock Options, Warrants and Restricted Stock Units (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Changes in Stock Option	The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2018 11,318,021 $ 0.112-120.00 6.75 years $ - $ 0.24 Options granted 22,882,500 $ 0.029 - $ - Options exercised - $ - - $ - Options expired (46,250 ) $ - - $ - Balance at September 30, 2019 34,154,271 $ 0.024-120.00 6.40 years $ 297,217 $ 0.15 Exercisable at September 30, 2019 28,713,021 $ 0.024-120.00 6.46 years $ 221,583 $ 0.15
Schedule of Changes in Stock Warrants	The following schedule summarizes the changes in the Company’s stock warrants: Warrants Outstanding Weighted Average Aggregate Weighted Number Of Shares Exercise Price Per Share Contractual Life Intrinsic Value Exercise Price Per Share Balance at December 31, 2018 23,052,472 $ 0.08-80.00 1.77 years $ - $ 0.08 Warrants granted 7.109,375 $ 0.04-0.08 - $ 0.06 Warrants exercised - $ - - $ Warrants expired/cancelled - $ - - $ Balance at September 30, 2019 30,161,847 $ 0.04-80.00 1.18 years $ - $ 0.10 Exercisable at September 30, 2019 30,161,847 $ 0.04-80.00 1.18 years $ - $ 0.10
Schedule of Changes in Restricted Stock Units	The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2018 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at September 30, 2019 262,500 $ 0.59

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 28, 2019	Dec. 22, 2017	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Reverse stock-split	1 for 8 stock-split
Revenue				$ 8,000		$ 8,000
Inventory
Production equipment capitalized cost						2,500
Fixed assets capitalized cost						1,500
Nonrefundable license fee			$ 10,000			$ 17,500
Royalties percentage, description						The increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%).
Economic life of the patent						10 years
Income from grants		$ 17,500					17,500
Research and development costs				$ 18,492	$ 2,455	$ 62,194	77,035
Advertising and marketing costs						$ 0	$ 13,700
Income tax description						The Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings.
Income tax federal corporate tax rate						21.00%
Reduction of net deferred tax assets						$ 3,300,000
Net Sales [Member]
Royalties percentage, description						The Company also agreed to change the royalty fee on net sales back to 1% on October 8, 2019.

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Schedule of Depreciation Estimated Useful Life (Details)	9 Months Ended
	Sep. 30, 2019
Production Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	3 years
Production Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	7 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Schedule of Future Minimum Royalties (Details)	Sep. 30, 2019USD ($)
Accounting Policies [Abstract]
2019	$ 10,000
2020	10,000
2021	10,000
2022	4,000
Total	$ 34,000

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Schedule of Dilutive Earnings Per Share (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	106,528,829	78,900,827
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	9,465,196	17,594
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	32,747,515	44,512,740
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	34,154,271	11,318,021
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	30,161,847	23,052,472

Going Concern (Details Narrativ

Going Concern (Details Narrative)	9 Months Ended
	Sep. 30, 2019USD ($)
Requires funding to maintain current operating activities	$ 2,300,000
Minimum [Member]
Capital	5,000,000
Maximum [Member]
Capital	$ 10,000,000

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	6 Months Ended	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Line Items]
Depreciation expense
Piece of Equipment [Member]
Property, Plant and Equipment [Line Items]
Proceeds from sale of equipment	$ 0
Equipment value	$ 0

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - Production Equipment [Member] - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Production equipment		$ 15,182
Less accumulated depreciation		(15,182)
Net fixed assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Sep. 24, 2019

Apr. 29, 2019

Mar. 27, 2019

Feb. 20, 2019

Jan. 24, 2019

Oct. 10, 2018

Aug. 09, 2018

Mar. 31, 2017

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Aug. 20, 2019

Jul. 05, 2019

Oct. 31, 2018

Oct. 19, 2018

Related Party Transaction [Line Items]

Accrued interest payable

$ 66,102

$ 66,102

$ 58,593

Debt instrument interest rate

8.00%

Note maturity date

Aug. 20, 2019

Debt conversion, amount converted

$ 3,240,661

Advances from related party

187,000

Proceeds from warrants

750,000

Debt discount

74,739

74,739

Notes payable to related party

187,000

187,000

Related party payables

38,710

38,710

38,610

Gain loss on conversion of debt

$ 394,618

526,222

Director [Member]

Related Party Transaction [Line Items]

Accrued interest payable

7,155

7,155

Debt instrument interest rate

8.00%

8.00%

8.00%

8.00%

Note maturity date

Jul. 5, 2020

Mar. 27, 2020

Jan. 24, 2020

Interest expenses, related party

7,155

Notes payable to related party

$ 29,000

$ 48,000

$ 60,000

$ 50,000

Debt term

1 year

1 year

1 year

Accounts Payable and Notes Payable [Member]

Related Party Transaction [Line Items]

Gain loss on conversion of debt

$ 35,400

Number of stock issued for settlement of debt

450,000

Number of stock issued for settlement of debt, value

$ 50,400

Number of warrant granted

225,000

Convertible Notes Payable [Member]

Related Party Transaction [Line Items]

Interest expenses, related party

36

$ 28,704

Series B Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Conversion price per share

$ 0.08

Common Stock [Member]

Related Party Transaction [Line Items]

Number of common stock issued for compensation

4,832,820

Warrant to purchase of common stock

2,416,410

Accrued compensation

$ 541,276

Number of warrants issued, value

238,973

Gain loss on conversion of debt

$ 586,936

Path Forward and Restructuring Agreement [Member]

Related Party Transaction [Line Items]

Conversion price per share

$ 0.032

Debt conversion, amount converted

$ 500,000

Path Forward and Restructuring Agreement [Member] | Series B Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Debt conversion, shares issued

385,302

Path Forward and Restructuring Agreement [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Debt conversion, shares issued

6,250,000

Path Forward and Restructuring Agreement [Member] | Warrant [Member]

Related Party Transaction [Line Items]

Debt conversion, shares issued

5,533,138

Warrant exercise price per share

$ 0.08

Old Related Party Note [Member]

Related Party Transaction [Line Items]

Accrued interest payable

1,054

1,054

Director and Major Stockholder [Member] | Related Party Note [Member]

Related Party Transaction [Line Items]

Accrued interest payable

$ 51,576

Debt instrument interest rate

10.00%

Note maturity date

May 9, 2018

Note maturity date, description

The note holder agreed to an extension of the due date until May 9, 2018

Conversion price per share

$ 0.104

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Accrued interest payable

$ 36

36

Debt instrument interest rate

8.00%

Note maturity date

Jan. 15, 2020

Advances from related party

20,000

Repayment of advance from related party

$ 5,000

Advances from related party, outstanding balance

$ 15,000

Proceeds from warrants

150,000

150,000

Debt discount

$ 3,721

$ 3,721

Debt instrument description

The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020.

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transaction (Details) - USD ($)	Sep. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Feb. 20, 2019	Jan. 31, 2019	Dec. 31, 2018	Mar. 31, 2017
Related Party Transaction [Line Items]
Principal					$ 100,000
Total Notes Payable, Net	$ 187,000
Accrued interest	66,102						58,593
Less: Debt Discount	(74,739)
Convertible notes payable, related party, net	11,475
Convertible Note Payable [Member]
Related Party Transaction [Line Items]
Principal	15,000
Accrued interest	1,090						1,054
Less: Debt Discount	(3,525)
Convertible notes payable, related party, net	11,475
Convertible Note Payable [Member] | Related Party One [Member]
Related Party Transaction [Line Items]
Principal	15,000
Accrued interest	36
Convertible Note Payable [Member] | Other Related Party Notes [Member]
Related Party Transaction [Line Items]
Principal
Accrued interest	1,054						1,054
Convertible Note Payable [Member] | Related Party Two [Member]
Related Party Transaction [Line Items]
Principal								$ 332,195
Accrued interest
Related Party Notes Payable [Member]
Related Party Transaction [Line Items]
Total Notes Payable, Net	187,000
Accrued interest	7,155
Related Party Notes Payable [Member] | Related Party Three [Member]
Related Party Transaction [Line Items]
Principal						$ 60,000
Total Notes Payable, Net	60,000
Accrued interest	3,266
Related Party Notes Payable [Member] | Related Party Four [Member]
Related Party Transaction [Line Items]
Principal				$ 48,000
Total Notes Payable, Net	48,000
Accrued interest	1,962
Related Party Notes Payable [Member] | Related Party Five [Member]
Related Party Transaction [Line Items]
Principal			$ 29,000
Total Notes Payable, Net	29,000
Accrued interest	976
Related Party Notes Payable [Member] | Related Party Six [Member]
Related Party Transaction [Line Items]
Principal		$ 50,000
Total Notes Payable, Net	50,000
Accrued interest	$ 951

Related Party Transactions - _2

Related Party Transactions - Schedule of Related Party Transaction (Details) (Parenthetical) - USD ($)	1 Months Ended
	Sep. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Mar. 31, 2017	Feb. 20, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Note, amount							$ 100,000
Note, interest rate							8.00%
Convertible Note Payable [Member]
Related Party Transaction [Line Items]
Note, amount	$ 15,000
Convertible Note Payable [Member] | Related Party One [Member]
Related Party Transaction [Line Items]
Note, amount	$ 15,000
Note, interest rate	8.00%
Note due date, description	January 2020
Convertible Note Payable [Member] | Related Party Two [Member]
Related Party Transaction [Line Items]
Note, amount						$ 332,195
Note, interest rate						10.00%
Note due date, description						May 2017
Related Party Notes Payable [Member] | Related Party Three [Member]
Related Party Transaction [Line Items]
Note, amount					$ 60,000
Note, interest rate					8.00%
Note due date, description					January 2020
Related Party Notes Payable [Member] | Related Party Four [Member]
Related Party Transaction [Line Items]
Note, amount				$ 48,000
Note, interest rate				8.00%
Note due date, description				March 2020
Related Party Notes Payable [Member] | Related Party Five [Member]
Related Party Transaction [Line Items]
Note, amount			$ 29,000
Note, interest rate			8.00%
Note due date, description			April 2020
Related Party Notes Payable [Member] | Related Party Six [Member]
Related Party Transaction [Line Items]
Note, amount		$ 50,000
Note, interest rate		8.00%
Note due date, description		July 2020

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2019	Aug. 20, 2019	May 31, 2019	Feb. 20, 2019	Oct. 30, 2018	Oct. 10, 2018	Jan. 31, 2018	Oct. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jul. 31, 2019	Dec. 31, 2018	Jul. 31, 2018	Apr. 19, 2018
Debt Instrument [Line Items]
Convertible notes payable	$ 415,166								$ 415,166		$ 415,166			$ 53,824
Debt discount	74,739								74,739		74,739
Debt conversion of convertible debt												$ 3,240,661
Debt instrument interest rate				8.00%
Debt principal amount				$ 100,000
Gain loss on conversion of debt										$ 394,618		526,222
Debt maturity date				Aug. 20, 2019
Proceeds from convertible debt												50,000
Amortization of BCF discount											16,327
Two Noteholders [Member]
Debt Instrument [Line Items]
Debt maturity date		Feb. 20, 2020
Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Principal amount, percentage								100.00%
Conversion price per share								$ 0.08
Path Forward Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, description						These shares were subject to a restriction on any sales below $0.16 through December 31, 2018 and will have volume limitations on any sales below $0.08 during the first six months of 2019.
Path Forward Agreement [Member] | Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion of debt into stock						2,610,453
Conversion price per share						$ 0.032
Convertible Note Payable [Member]
Debt Instrument [Line Items]
Interest expenses											7,509	$ 100,826
Debt discount	3,525								3,525		3,525
Debt principal amount	15,000								15,000		15,000
May 2017 Notes [Member]
Debt Instrument [Line Items]
Convertible notes payable	3,136,506								3,136,506		3,136,506
Debt discount	2,419,240								2,419,240		$ 2,419,240
Note due date, description											December 2017 due date which was extended to May 2018.
November 2017 Note [Member]
Debt Instrument [Line Items]
Convertible notes payable	166,666								166,666		$ 166,666
Debt discount	92,004								92,004		92,004
Principal amount, percentage							130.00%
Repurchase of notes																$ 228,332
Convertible Secured Debentures and Convertible Promissory Note [Member] | Path Forward Agreement [Member]
Debt Instrument [Line Items]
Debt conversion of convertible debt						$ 2,253,538
Conversion of debt into stock						37,792,407
Convertible Notes [Member]
Debt Instrument [Line Items]
Convertible notes payable															$ 50,000
Conversion of debt into stock					1,500,000
Conversion price per share					$ 0.112
Debt instrument interest rate															8.00%
Capital raise															$ 500,000
Debt principal amount					$ 60,000
Interest and other costs					10,000
Gain loss on conversion of debt					$ 108,916
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Convertible notes payable	$ 300,000		$ 50,000						$ 300,000		$ 300,000		$ 300,000
Debt discount			$ 10,000
Conversion price per share	$ 0.04		$ 0.032						$ 0.04		$ 0.04		$ 0.04
Debt instrument interest rate	8.00%		8.00%						8.00%		8.00%		8.00%
Convertible Promissory Note [Member] | Qualified Financing [Member]
Debt Instrument [Line Items]
Debt maturity date			Oct. 30, 2019
Proceeds from convertible debt			$ 250,000
Convertible Promissory Note [Member] | Qualified Financing [Member] | Note Holders [Member]
Debt Instrument [Line Items]
Shares issued price per share			$ 1.20
Number of warrants issued			625,000
Warrants exercise price			$ 0.04
Warrants term			2 years
Fair value of warrants			$ 12,592
Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member]
Debt Instrument [Line Items]
Debt maturity date	Jan. 15, 2020
Proceeds from convertible debt	$ 250,000
Shares issued price per share	$ 1.20								$ 1.20		$ 1.20
Number of warrants issued	3,000,000								3,000,000		3,000,000
Warrants term	2 years								2 years		2 years
Fair value of warrants	$ 91,716								$ 91,716		$ 91,716
Debt instrument beneficial conversion feature	$ 59,957
Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member] | Minimum [Member]
Debt Instrument [Line Items]
Warrants exercise price	$ 0.06								$ 0.06		$ 0.06
Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member] | Maximum [Member]
Debt Instrument [Line Items]
Warrants exercise price	$ 0.08								$ 0.08		$ 0.08

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal	$ 415,166	$ 53,824
Accrued interest	66,102	58,593
Penalties on notes in default principal (net)	10,166
Penalties on notes in default accrued interest	8,824
Less: original issue discount	(1,970)
Less: BCF Discount	(43,630)
Less: debt discount	(74,739)
Convertible notes payable, principal (net)	294,827	53,824
Convertible notes payable, accrued interest	66,102	58,593
Convertible Notes Payable One [Member]
Debt Instrument [Line Items]
Principal	45,000	45,000
Accrued interest	38,631	34,603
Convertible Notes Payable Two [Member]
Debt Instrument [Line Items]
Principal
Accrued interest	17,341	17,341
Convertible Notes Payable Three [Member]
Debt Instrument [Line Items]
Principal
Accrued interest	5,953	5,953
Convertible Notes Payable Four [Member]
Debt Instrument [Line Items]
Principal
Accrued interest	696	696
Convertible Notes Payable Five [Member]
Debt Instrument [Line Items]
Principal	60,000
Accrued interest	1,600
Convertible Notes Payable Six [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	874
Convertible Notes Payable Seven [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	230
Convertible Notes Payable Eight [Member]
Debt Instrument [Line Items]
Principal	38,000
Accrued interest	174
Convertible Notes Payable Nine [Member]
Debt Instrument [Line Items]
Principal		25,000
Accrued interest		109
Convertible Notes Payable Ten [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	208
Convertible Notes Payable Eleven [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	197
Convertible Notes Payable Twelve [Member]
Debt Instrument [Line Items]
Principal	37,000
Accrued interest	$ 89

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

Aug. 31, 2012

Jul. 31, 2012

Sep. 30, 2019

Jul. 31, 2019

May 31, 2019

Mar. 31, 2016

Dec. 31, 2015

Oct. 31, 2015

Feb. 20, 2019

Dec. 31, 2018

Jan. 31, 2016

May 31, 2015

Debt Instrument [Line Items]

Debt principal amount

$ 100,000

Original issue discount

$ (1,970)

Convertible Notes Payable One [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 1,060,000

$ 1,060,000

Debt conversion price per share

$ 4.60

$ 4.60

Debt interest rate

12.00%

12.00%

Debt maturity date description

January 2014

December 2013

Convertible Notes Payable Two [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 605,000

$ 605,000

Debt conversion price per share

$ 1

$ 1

Debt maturity date description

September 30, 2015

Convertible Notes Payable Two [Member] | Minimum [Member]

Debt Instrument [Line Items]

Debt interest rate

8.00%

8.00%

Convertible Notes Payable Two [Member] | Maximum [Member]

Debt Instrument [Line Items]

Debt interest rate

10.00%

10.00%

Convertible Notes Payable Three [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 613,000

$ 613,000

Debt conversion price per share

$ 1

$ 1

Debt interest rate

8.00%

8.00%

Debt maturity date description

June 30, 2016

Debt discount

0

$ 560,913

Convertible Notes Payable Four [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 345,000

$ 345,000

Debt conversion price per share

$ 1

$ 1

Debt interest rate

8.00%

8.00%

Debt maturity date description

June 30, 2016

Convertible Notes Payable Five [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 60,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

October 30, 2019

Convertible Notes Payable Six [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Seven [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Eight [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 38,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Nine [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 25,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Ten [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Eleven [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Twelve [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 37,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Promissory Notes Payable (Detai

Promissory Notes Payable (Details Narrative) - USD ($)	Aug. 20, 2019	Feb. 20, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Debt Instrument [Line Items]
Debt principal amount		$ 100,000
Debt maturity date		Aug. 20, 2019
Debt instrument interest rate		8.00%
Interest expense			$ 96,271	$ 60,752		$ 134,739	$ 5,626,892
Amortized debt discount						$ 66,969	$ 791,937
Number of warrants received	750,000
Accrued interest paid	$ 4,000
Two Noteholders [Member]
Debt Instrument [Line Items]
Debt maturity date	Feb. 20, 2020
Debt instrument, interest rate increase	15.00%
Noteholders One [Member]
Debt Instrument [Line Items]
Number of warrants received	375,000
Noteholders Two [Member]
Debt Instrument [Line Items]
Number of warrants received	375,000
Promissory Notes One [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 50,000
Promissory Notes Two [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 50,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Interest expense					$ 2,842
Warrant to purchase of shares			1,250,000			1,250,000
Fair value of warrants debt discount			$ 28,721			$ 28,721
Amortized debt discount						$ 28,721

Promissory Notes Payable - Sche

Promissory Notes Payable - Schedule of Promissory Notes Payable, Net (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Principal (net)	$ 100,000
Accrued Interest	66,102	58,593
Debt discount	74,739
Promissory Notes Payable One [Member]
Principal (net)	100,000
Accrued Interest	1,640
Debt discount
Promissory Notes Payable [Member]
Principal (net)	100,000
Accrued Interest	1,640
Debt discount

Promissory Notes Payable - Sc_2

Promissory Notes Payable - Schedule of Promissory Notes Payable, Net (Details) (Parenthetical) - USD ($)	1 Months Ended
	Feb. 28, 2019	Feb. 20, 2019
Note, amount		$ 100,000
Note, interest rate		8.00%
Promissory Notes Payable One [Member]
Note, amount	$ 50,000
Promissory Notes Payable Two [Member]
Note, amount	50,000
Promissory Notes Payable [Member]
Note, amount	$ 100,000
Note due date, description	August 2019
Note, interest rate	8.00%
Debt instrument, interest rate increase	15.00%
Promissory Notes Payable [Member] | Extended Maturity [Member]
Note due date, description	extended to February 2020

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jun. 28, 2019	Mar. 28, 2019	Mar. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jun. 30, 2015	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 27, 2019	Oct. 08, 2018	Jun. 30, 2016	Sep. 30, 2015
Class of Stock [Line Items]
Common stock shares authorized							950,000,000			2,000,000,000				950,000,000		2,000,000,000
Common stock par value							$ 0.001			$ 0.001				$ 0.001		$ 0.001
Common stock shares issued							178,585,821			163,445,736				178,585,821		163,445,736
Common stock shares outstanding							178,585,821			163,445,736				178,585,821		163,445,736
Reverse stock split	1 for 8 stock-split
Preferred stock shares authorized							20,000,000			20,000,000				20,000,000		20,000,000
Preferred stock par value							$ 0.001			$ 0.001				$ 0.001		$ 0.001
Gross proceeds from preferred stock														$ 50,000
Stock issued for accounts payable and accrued expenses				$ 562,500			$ 22,500			$ 1,665,296
Stock issued for accounts payable and accrued expenses, shares				22,500
Number of stock issued for services				312,500												449
Number of stock issued for services, value				$ 12,500			12,500						$ 449			$ 1,250
Gain loss on conversion of debt											$ 394,618				$ 526,222
Stock issued during period for conversion of shares, shares
Stock issued during period for conversion of shares, value
Number of shares issued, value									$ 100,000	738,140
Warrant [Member]
Class of Stock [Line Items]
Number of stock issued for services														84,375
Number of stock issued for services, value														$ 3,792
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued				13,015,225
Board of Directors [Member]
Class of Stock [Line Items]
Common stock shares authorized		950,000,000															2,000,000,000
Reverse stock split		reverse 1-for-8 stock split
Accredited Investors [Member]
Class of Stock [Line Items]
Proceeds from equity financing				$ 100,000
Accredited Investors [Member] | Warrant [Member]
Class of Stock [Line Items]
Warrant to purchase of common stock				1,250,000
Accredited Investors [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued				1,250,000
Officers and Consultants [Member]
Class of Stock [Line Items]
Gain loss on conversion of debt																1,256,972
Number of common stock for accrued compensation, value																1,665,285
Settlement of Debt [Member]
Class of Stock [Line Items]
Settlement and conversion of debt, value																3,545,378
Convertible debt accrued interest																506,245
Derivative liabilities										$ 4,823,363						4,823,363
Gain loss on conversion of debt																$ 1,694,005
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					5,000,000		5,000,000			5,000,000				5,000,000		5,000,000		5,000,000
Preferred stock par value																		$ 0.001
Preferred stock, liquidation preference per share					$ 1
Conversion price per share					$ 0.08
Voting percentage					Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage					100.00%
Number of shares issued upon conversion				1,041,218
Preferred shares exchange				821,292
Settlement and conversion of debt																2,995,755
Preferred stock issued for cash																110,000
Preferred stock issued for cash, value																$ 55,000
Series B Convertible Preferred Stock [Member] | Accredited Investors [Member]
Class of Stock [Line Items]
Number of shares issued				100,000
Series B Convertible Preferred Stock [Member] | Officers and Consultants [Member]
Class of Stock [Line Items]
Number of common stock for accrued compensation																$ 200,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized			5,000,000				5,000,000		5,000,000	5,000,000				5,000,000		5,000,000	5,000,000
Preferred stock par value																	$ 0.001
Preferred stock, liquidation preference per share			$ 1						$ 1
Conversion price per share			$ 0.08						$ 0.08
Voting percentage			Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage			100.00%
Number of shares issued				821,292
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized							5,000,000			5,000,000				5,000,000		5,000,000			2,500,000	2,500,000
Preferred stock, liquidation preference per share																				$ 5
Conversion price per share																				$ 4
Gross proceeds from preferred stock						$ 5,000,000
Voting percentage						Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage						100.00%
Stock issued during period for conversion of shares, shares																1,532,476
Stock issued during period for conversion of shares, value																$ 4,678,380
Conversion of debt, shares																1,225,981
Series A Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																			5,000,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued																17,078,500
Warrant to purchase of common stock										2,416,410						2,416,410
Settlement and conversion of debt																128,528,788
Gain loss on conversion of debt																$ 586,936
Number of shares issued, value																683,140
Common Stock [Member] | Officers and Consultants [Member]
Class of Stock [Line Items]
Number of common stock for accrued compensation																$ 7,782,820

Common Stock Options, Warrant_3

Common Stock Options, Warrants and Restricted Stock Units (Details Narrative) - USD ($)	Jun. 28, 2019	Jun. 21, 2019	Sep. 30, 2019	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock-split	1 for 8 stock-split
Stock based compensation					$ 457,949				$ 463,917	$ 45,400
Debt discount			$ 74,739		74,739				74,739
Interest expense					96,271	$ 60,752			$ 134,739	5,626,892
Number of issued for services, shares				312,500							449
Number of issued for services				$ 12,500	12,500		$ 449				$ 1,250
Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant granted issuance of shares									5,025,000
Interest expense								$ 2,842
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation									$ 460,125	45,400
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued for extension of notes payable									750,000
Interest expense									$ 25,656
Number of issued for services, shares									84,375
Number of issued for services									$ 3,792
Warrant [Member] | Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt discount			136,749		136,749				136,749
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock expense									0	$ 104,410
Stock options expense yet to be recognized			$ 155,400		$ 155,400				$ 155,400
Settlement Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options issued									1,000,000
Options issued for settlement of accounts payable									$ 33,829
Option vesting period									10 years
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options issued			382,500
Stock options vesting period description			vest through June 30, 2020
Number of stock options expired		46,250
Dr. Korenko [Member] | 2015 Omnibus Securities and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options issued									21,000,000
Stock options vesting period description									The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019 and December 31, 2019); (ii) 25% upon the Company filing a patent; and (iii) 25% upon the first commercial sale of IsoPet®.
Fair value of options									$ 585,144
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options issued									500,000
Fair value of options									$ 16,915
Option vesting period									10 years
Accredited Investors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant granted issuance of shares									1,250,000

Common Stock Options, Warrant_4

Common Stock Options, Warrants and Restricted Stock Units - Schedule of Changes in Stock Option (Details) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Options Outstanding Beginning Balance | shares	11,318,021
Number of Options granted | shares	22,882,500
Number of Options exercised | shares
Number of Options expired | shares	(46,250)
Number of Shares Options Outstanding Ending Balance | shares	34,154,271
Number of Shares Options Exercisable | shares	28,713,021
Exercise Price Per Share granted	$ 0.029
Exercise Price Per Share exercised
Exercise Price Per Share expired
Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning	6 years 9 months
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending	6 years 4 months 24 days
Weighted Average Remaining Contractual Life (in years) Exercisable	6 years 5 months 16 days
Aggregate Intrinsic Value Outstanding Beginning | $
Aggregate Intrinsic Value Outstanding Ending | $	297,217
Aggregate Intrinsic Value Exercisable | $	$ 221,583
Weighted Average Exercise Price Per Share Outstanding Beginning	$ 0.24
Weighted Average Exercise Price Per Share Options granted
Weighted Average Exercise Price Per Share Options exercised
Weighted Average Exercise Price Per Share Options expired
Weighted Average Exercise Price Per Share Outstanding Ending	0.15
Weighted Average Exercise Price Per Share Exercisable	0.15
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	0.112
Exercise Price Per Share granted
Exercise Price Per Share exercised
Exercise Price Per Share expired
Exercise Price Per Share Outstanding Ending Balance	0.024
Exercise Price Per Share Exercisable	0.024
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	120
Exercise Price Per Share granted
Exercise Price Per Share exercised
Exercise Price Per Share expired
Exercise Price Per Share Outstanding Ending Balance	120
Exercise Price Per Share Exercisable	$ 120

Common Stock Options, Warrant_5

Common Stock Options, Warrants and Restricted Stock Units - Schedule of Changes in Stock Warrants (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Warrants Outstanding Beginning | shares	23,052,472
Number of Shares, Warrants granted | shares	7,109,375
Number of Shares, Warrants exercised | shares
Number of Shares, Warrants expired/cancelled | shares
Number of Shares, Warrants Outstanding Ending | shares	30,161,847
Number of Shares, Warrants Exercisable Ending | shares	30,161,847
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	1 year 9 months 7 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	1 year 2 months 5 days
Weighted Average Remaining Contractual Life Warrants Exercisable	1 year 2 months 5 days
Aggregate Intrinsic Value Outstanding Beginning | $
Aggregate Intrinsic Value Outstanding Ending | $
Aggregate Intrinsic Value Exercisable | $
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning	$ 0.08
Weighted Average Exercise Price Per Share Exercise Price Warrants granted	0.06
Weighted Average Exercise Price Per Share Exercise Price Warrants exercised
Weighted Average Exercise Price Per Share Exercise Price Warrants expired/cancelled
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending	0.10
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable	0.10
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	0.08
Exercise Price Per Share Warrants granted	0.04
Exercise Price Per Share Warrants Outstanding Ending	0.04
Exercise Price Per Share Exercisable	0.04
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	80
Exercise Price Per Share Warrants granted	0.08
Exercise Price Per Share Warrants Outstanding Ending	80
Exercise Price Per Share Exercisable	$ 80

Common Stock Options, Warrant_6

Common Stock Options, Warrants and Restricted Stock Units - Schedule of Changes in Restricted Stock Units (Details) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, RSU's Outstanding Beginning | shares	262,500
Number of Shares, RSU's Granted | shares
Number of Shares, RSU's Vested | shares
Number of Shares, RSU's Forfeited | shares
Number of Shares, RSU's Outstanding Ending | shares	262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning | $ / shares	$ 0.59
Weighted Average Grant Date Fair Value, RSU's Granted | $ / shares
Weighted Average Grant Date Fair Value, RSU's Vested | $ / shares
Weighted Average Grant Date Fair Value, RSU's Forfeited | $ / shares
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending | $ / shares	$ 0.59

Commitment (Details Narrative)

Commitment (Details Narrative) - USD ($)	Jun. 28, 2019	Jun. 04, 2019	Sep. 30, 2019
Reverse stock-split	1 for 8 stock-split
Dr. Korenko [Member] | 2015 Omnibus Securities and Incentive Plan [Member]
Number of stock options granted shares			21,000,000
Stock options vesting period description			The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019 and December 31, 2019); (ii) 25% upon the Company filing a patent; and (iii) 25% upon the first commercial sale of IsoPet®.
Employment Agreement [Member] | Dr. Michael K. Korenko [Member]
Agreement term description		The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement.
Compensation amount		$ 180,000
Compensation payable in monthly intervals		$ 120,000
Compensation payable description		Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $180,000. Of this amount, $120,000 is booked in monthly intervals and the remaining balance is only paid upon the Company achieving a cash balance that exceeds $1,000,000. The Company has elected to record the compensation as $120,000, and upon achieving the milestone of $1,000,000 in cash balances, will record the deferred compensation at that time.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - shares	Oct. 08, 2019	Oct. 07, 2019	Oct. 31, 2019	Mar. 31, 2018
Subsequent Event [Line Items]
Conversion of preferred stock into common stock, shares
Subsequent Event [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of preferred stock into common stock, shares			430,000
Subsequent Event [Member] | Restricted Stock Units [Member]
Subsequent Event [Line Items]
Restricted common stock, shares			385,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of preferred stock into common stock, shares			5,375,000
Subsequent Event [Member] | Battelle Memorial Institute [Member] | License Agreement [Member]
Subsequent Event [Line Items]
Decrease in royalty percentage	1.00%	2.00%
Minimum royalties description	Minimum royalties through 2022.